NCT04507191

Brief Summary

the main purpose is to study the prognostic effect of PDL1 in ovarian cancer especially HGSC. Therefore, in the present study the investigators analyzed the expression of PDL1in HGSC by immunohistochemistry, and results were correlated to prognosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2012

Completed
7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2019

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

August 4, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

August 11, 2020

Completed
Last Updated

August 11, 2020

Status Verified

August 1, 2020

Enrollment Period

7 years

First QC Date

August 4, 2020

Last Update Submit

August 6, 2020

Conditions

Ovarian Cancer

Outcome Measures

Primary Outcomes (1)

  • number of slides stained positive to PDL1 marker

    using immunohistochemical staining for PDL1 markers for all slides of cases with ovarian tumor

    7 years from 2012 to 2019

Secondary Outcomes (1)

  • correlation between PDL1 expression to clinicopathological parameters of ovarian high grade serous carcinoma

    7 years from 2012 to 2019

Other Outcomes (1)

  • correlation between PDL1 expression to prognosis of ovarian high grade serous carcinoma

    43.3 months

Interventions

immunohistochemical stainingDIAGNOSTIC_TEST

immunohistochemical staining of programmed death-ligand 1 (PDL1) marker

Eligibility Criteria

Age50 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all patients diagnosed with primary serous ovarian cancer and subjected to staging laparotomy

You may qualify if:

  • patients diagnosed with primary ovarian cancer

You may not qualify if:

  • patients with metastatic ovarian cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of Medicine, Port Said University

Port Said, 42511, Egypt

Location

MeSH Terms

Conditions

Ovarian Neoplasms

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsOvarian DiseasesAdnexal DiseasesGenital Diseases, FemaleFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesGenital Neoplasms, FemaleUrogenital NeoplasmsGenital DiseasesEndocrine System DiseasesGonadal Disorders

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer of pathology

Study Record Dates

First Submitted

August 4, 2020

First Posted

August 11, 2020

Study Start

December 1, 2012

Primary Completion

December 1, 2019

Study Completion

December 30, 2019

Last Updated

August 11, 2020

Record last verified: 2020-08

Locations

EG(1)